Business Insider

Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1/2 Clinical Trial Evaluating Topical Spray-On Antibiotic RECCE® 327 on Chronic Burn Wounds

Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western Australia Study led by world leading burn treatment specialists Study will assess safety and efficacy of RECCE ® ...
Business Insider

Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections

Human Research Ethics Committee approval received for Phase II trial of R327 for acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot and wound infections New site ...
Hosted on MSN

Recce Pharmaceuticals Reports Promising Preclinical Results for Inhaled RECCE® 327

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
WGN-TV

Recce Pharmaceuticals Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE® 327 in Patients with Diabetic Foot Infections

Phase 1/2 trial of RECCE ® 327 (R327) is approved to start at the South West Sydney Limb Preservation and Wound Research Unit, located at the Ingham Institute of Medical Research Study will assess the ...
The Australian

Recce locks in major Hong Kong patent for anti-infectives

This new patent strengthens Recce’s intellectual property footprint across Asia, supporting its strategy to access high-growth ASEAN markets. The patent claims cover Recce Pharmaceuticals (ASX:RCE) ...